Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use

Abstract

The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.

1 - 7 . (canceled) 
     
     
         8 . A method of treating and/or preventing a disease selected from Amyotrophic lateral sclerosis and parkinsonism-dementia complex, Chronic traumatic encephalopathy, cerebral amyloid angiopathy, Dementia pugilistica, Familial British Dementia, Familial Danish Dementia, Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallervorden-Spatz disease, inclusion body myositis, multiple system atrophy, Steinert Myotonic dystrophy, Myotonic dystrophy type II, Neurodegeneration with brain iron accumulation, Niemann-Pick disease, Non-Guamanian motor neuron disease with neurofibrillary tangles, Postencephalitic parkinsonism, Subacute sclerosing panencephalitis, multi-infarct dementia, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound of Formula I 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         9 . A method according to  claim 8 , wherein the disease is Steinert Myotonic dystrophy and Myotonic dystrophy type II. 
     
     
         10 . A method according to  claim 8 , wherein the disease is Steinert Myotonic dystrophy. 
     
     
         11 . A method according to  claim 8 , wherein the compound of Formula I is administered as a composition of the compound or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. 
     
     
         12 . A method for decreasing pathological Tau protein phosphorylation in a patient suffering from Amyotrophic lateral sclerosis and parkinsonism-dementia complex, Chronic traumatic encephalopathy, cerebral amyloid angiopathy, Dementia pugilistica, Familial British Dementia, Familial Danish Dementia, Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallervorden-Spatz disease, inclusion body myositis, multiple system atrophy, Steinert Myotonic dystrophy, Myotonic dystrophy type II, Neurodegeneration with brain iron accumulation, Niemann-Pick disease, Non-Guamanian motor neuron disease with neurofibrillary tangles, Postencephalitic parkinsonism, Subacute sclerosing panencephalitis, multi-infarct dementia, chronic traumatic encephalopathy (CTE) or traumatic brain injury (TBI), in need thereof, comprising administering to said patient an effective amount of a compound of Formula I 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         13 . A method according to  claim 12 , wherein the disease is Steinert Myotonic dystrophy and Myotonic dystrophy type II. 
     
     
         14 . A method according to  claim 12 , wherein the disease is Steinert Myotonic dystrophy.